Finding a way to slow or even stop Alzheimer’s disease is one of the most difficult challenges facing medicine today. Many research and clinical trials have led to promising results over the years, while others have produced disappointing findings. But what if there were a way to get more out of these trials—even the ones with less-than-promising results? What if there were a better way to determine if a drug is hitting its intended target?

In 2008, Cynthia Toth, MD, set out to develop optical coherence tomography (OCT), a technology that bounces light waves off different parts of the eye, providing a finely detailed look inside the eye’s tissues for pediatric use. She is now recognized as the founder of pediatric OCT. For infants and children.

For many years, the late Neil L. Spector, MD, who was a leading cancer researcher at Duke Cancer Institute, struggled with Lyme disease. Initially, he was misdiagnosed and when finally treated with antibiotics, some of his symptoms improved but his heart was irreparably damaged due to Lyme carditis, a condition that occurs when Lyme disease bacteria enter the tissues of the heart.

Michael Boyce, PhD, associate professor of biochemistry, never expected to be studying the lungs. He is an expert in glycobiology—the intricate mechanisms behind how sugars attach to proteins, and the role these sugars play in sending signals that influence cell biology, organ function, and more.